Harbour Investments’s Immuneering IMRX Stock Holding History

Harbour Investments’s Portfolio IMRX Stock Details IMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-25	Closed	-$184	–	3272
2023 Q4	$184	Hold	25	–	–	﹤0.01%	3015
2023 Q3	$192	Buy	+25	New	+$230	﹤0.01%	2888

Other funds holding IMRX

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HighVista Strategies Boston, Massachusetts $362M AUM 230.96% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Harbour Investments's IMRX Position: Q1 2024 in Review

Harbour Investments sold out of Immuneering (IMRX) in Q1 2024, closing a stake of 25 shares — an estimated $184 sold.

Harbour Investments first reported a position in IMRX in Q3 2023 and held it in 2 quarters. The position peaked at $192 in Q3 2023. 51 funds tracked by Wall St. Rank hold IMRX as of Q1 2024.

Harbour Investments reported no remaining Immuneering position as of Q1 2024 after selling out during the quarter.
Harbour Investments sold 25 Immuneering shares in Q1 2024, an estimated $184.
Harbour Investments first reported a position in Immuneering in Q3 2023 and held it in 2 quarters.
Harbour Investments's Immuneering position peaked at $192 in Q3 2023.
51 funds tracked by Wall St. Rank held Immuneering as of Q1 2024.

Based on Harbour Investments's 13F filing for Q1 2024, filed 22 Jul 2024.